Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …

Coronary artery disease (CAD) is one of the leading causes of death globally, and
antiplatelet therapy is crucial for both its prevention and treatment. Antiplatelet drugs such as …

Multiple guidelines and consensus papers have addressed the role of antithrombotic
strategies in patients with established coronary artery disease (CAD). Since evidence and …

Antiplatelet therapy after percutaneous coronary intervention (PCI) has been changing in
parallel with the development of drug-eluting stents (DES) and antiplatelet agents. The …

Introduction Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention
(PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However …

Dual antiplatelet therapy (DAPT) is a therapeutic cornerstone to prevent stent thrombosis
following percutaneous coronary intervention (PCI) for coronary artery disease (CAD) …

Background Several trials demonstrated that aspirin monotherapy compared with aspirin
plus clopidogrel is associated with a lower incidence of bleeding without an increased risk of …

Abstract Purpose of Review Drug-eluting stents are used in nearly all cases of percutaneous
coronary revascularization and have been shown to be superior to balloon angioplasty or …

Background Clopidogrel was superior to aspirin monotherapy in secondary prevention after
percutaneous coronary intervention (PCI). Objectives The purpose of this study was to …

Cardiologists are encountering a growing number of cancer patients with ischaemic heart
disease (IHD). Several factors account for the interrelationship between these two …